Explore ›
Finding
Finding
null
There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in the overall cohort (between-group p=0.57). In those with low baseline BFV (<27.6 cm/sec), the candesartan effect was significant (between-group p=0.03).
| Effect size | Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec |
| Follow-up | 12 months |
| Comparator | Lisinopril (10-40 mg/day) and hydrochlorothiazide (12.5-25 mg/day) |
| Effect summary | null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec |
| Effect modifiers | [{"modifier": "Baseline cerebral blood flow velocity", "interaction_p": "p=0.03 in low-BFV subgroup vs p=0.57 overall", "direction": "amplifies", "stratum_details": "Low BFV (<27.6 cm/sec median): candesartan +2.79 cm/sec, between-group p=0.03. Overall cohort: between-group p=0.57.", "plain_language": "Candesartan's brain blood flow benefit was concentrated in people who had the worst blood flow to start with \u2014 those with already-low cerebral perfusion saw the biggest improvement.", "annotation_notes": "Pre-defined subgroup analysis per protocol. N=23 in low-BFV subgroup."}] |
Connected entities
Interventions
Conditions
Outcomes
Populations
Source
PMC3608194
Antihypertensive therapy and cerebral hemodynamics in Executive Mild Cognitive Impairment: results of a Pilot randomized clinical trial